FDA Inspection
Xellia (Taizhou) PharmaceuticalsXellia (Taizhou) Pharmaceuticals – FDA Inspection, Apr 6, 2018
Record Details
This FDA Inspection record concerns Xellia (Taizhou) Pharmaceuticals, with an inspection on April 6, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · efd3b62d-c1cc-45b9-a741-0d826895654f
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1051248
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Xellia (Taizhou) Pharmaceuticals
4| Date | Classification | Office | Project area |
|---|---|---|---|
| July 3, 2026 | Not classified | Office of Inspections and Investigations | |
| March 26, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 20, 2012 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 27, 2009 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Xellia (Taizhou) Pharmaceuticals
- FDA Inspection 1330508 - 2026-07-03
- FDA Inspection 923425 - 2015-03-26
- FDA Inspection 801705 - 2012-09-20
- FDA Inspection 570393 - 2009-02-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.